Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla, +11

Leukemia

Dose-escalation StudyHematological MalignancyOncologyOral PanobinostatMedicine +6

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

Dana E. Rathkopf, Bryan Wong, Robert W. Ross, +7

Cancer Chemotherapy and Pharmacology

UrologyOncologyGenitourinary CancerOral PanobinostatCastration-resistant Prostate Cancer +2

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

Sally Clive, Margaret M. Woo, Thomas Nydam, +3

Cancer Chemotherapy and Pharmacology

OncologyPancreatic CancerMedicineAdvanced Cancer PatientsActive Pan-deacetylase Inhibitor +6

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, Andrew Spencer, H. Miles Prince, +9

Blood

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

Seongwook Jeong, Margaret M. Woo, David A. Flockhart, +1

Cancer Chemotherapy and Pharmacology

Major Oxidative MetaboliteMedicinal ChemistryPharmacological StudyBiochemistryMedicine +6

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Paul Hamberg, Margaret M. Woo, Lin‐Chi Chen, +8

Cancer Chemotherapy and Pharmacology

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

Sunil Sharma, Joachim Beck, Monica Mita, +5

Investigational New Drugs

Lymphoid NeoplasiaSurgical OncologySolid TumorsMedicineIntravenous Panobinostat +5

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

Geoffrey I. Shapiro, Richard C. Frank, Uday B. Dandamudi, +6

Cancer Chemotherapy and Pharmacology

NutritionAdvanced CancerOncologyPancreatic CancerMedicine +4

A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers

Yoichiro Ogama, Tomoko Mineyama, Asuka Yamamoto, +4

International Journal of Hematology

Drug SafetyHealthy Japanese VolunteersPharmacologyClinical PharmacologyRandomized Dose-escalation Study +3

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors

Marina Savelieva, Margaret M. Woo, Horst Schran, +3

European Journal of Clinical Pharmacology